Articles tagged with Cancer Patients
A randomized clinical trial found that flushing the bladder with a chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning. The study, published in JAMA, showed a 34% reduction in the risk of recurrence for patients receiving the treatment.
The center aims to study ways to reduce cancer risk among underserved individuals and improve outcomes among those with a diagnosis, utilizing tools like mobile health technology.
Cancer remains a significant concern as the HIV-infected population ages. By 2030, prostate and lung cancers are projected to be the most common cancers among individuals with HIV, due to their weakened immune systems.
A new study suggests that shifting cancer diagnosis from emergency hospital admissions to GP referrals could save thousands of lives and £2,130 per life saved. The shift would come at a small additional cost to the NHS.
Pancreatic cancer researchers and clinicians will work together to build a state-wide biobank, collecting data from diverse patient groups to minimize disparities and personalize care. The goal is to develop more effective therapeutic strategies tailored to individual needs, improving survival rates and quality of life.
The GlobalSurg3 study will pool data from hundreds of hospitals worldwide to compare surgery quality and highlight ways to improve patient care. The initiative aims to provide high-quality surgical care to millions of patients diagnosed with breast, gastric, or colon cancer annually.
Early intervention after completed clinical staging leads to increased survival rates in non-small cell lung cancer patients. Surgery within eight weeks from diagnosis significantly improves overall survival.
A study by Dana-Farber Cancer Institute and Broad Institute identified five genetic subtypes of diffuse large B cell lymphoma, which can help predict individual patient outcomes and guide personalized treatment. The analysis revealed clear links between specific genetic signatures and how patients respond to standard treatment.
A multi-center study discovered how adenosine to inosine (A-to-I) RNA editing contributes to protein diversity in breast cancer, increasing cancer cell proliferation and invasion. The findings suggest that individualizing therapies for each patient is reliant upon a better understanding of the protein genome.
A new review by Boston University School of Public Health researchers found that less than one-fifth of participants in cancer-related clinical trials are obese. Obesity was associated with an increased risk of progression, recurrence, and death for specific cancer types.
Researchers at University of Pennsylvania School of Medicine have identified five strategies to reduce unplanned acute care for cancer patients, including leveraging advanced big data analytics, team-based care, and early palliative care. These best practices aim to improve patient experience and reduce hospital utilization.
Research suggests that tiny differences in patient position during radiotherapy can lead to reduced survival chances, particularly when tumours are close to vital organs like the heart. Tightening treatment guidelines could improve survival rates by ensuring more accurate patient positioning.
A combination of XL888, a HSP90 inhibitor, and vemurafenib, a BRAF inhibitor, was found to be safe and effective in treating advanced melanoma patients, with 75% experiencing a response. The treatment resulted in manageable toxicities and durable responses.
A new University of Kansas research effort has resulted in a low-cost, reliable blood test that uses a small plastic chip to deliver diagnostic information similar to bone biopsies. The test has the potential to eliminate the need for invasive bone biopsies and guide treatment for multiple myeloma and other cancers.
A brief bedside visual art intervention (BVAI) improved mood and reduced pain and anxiety in patients with haematological cancers. The study found significant improvements in positive mood and pain scores, as well as decreases in negative mood and anxiety.
A new study suggests that adolescents and young adults with acute leukemia have a survival advantage when receiving treatment at pediatric cancer centers versus adult centers, particularly those affiliated with the National Cancer Institute. This is due to the more experienced care teams in these settings.
A new neuropathy measurement tool has been developed and found effective in quantifying symptoms and treatment efficacy. Minor revisions can improve its validity and universality for adoption in clinics and research settings.
A peer-reviewed study published in Oncotarget found that OncoDNA's comprehensive testing and analysis services, combining multiple biomarkers, increased oncologists' ability to make informed treatment decisions. The study showed a significant improvement in overall survival for late-stage patients, from six months to over 12 months.
The Global ROS1 Initiative is a patient-researcher collaboration that aims to accelerate research on ROS1 cancer. Members have contributed tumor samples and participated in epidemiological surveys, providing valuable insights into the disease.
A new blood test biomarker has been developed to distinguish between benign and malignant lung tumors with 98% accuracy. This breakthrough technology allows healthcare providers to confidently diagnose and treat patients with low-to-moderate risk nodules, reducing the need for invasive procedures.
A study published in Circulation found that patients with acute thrombosis in the leg are at a three-fold higher risk of developing cancer during the first six months after the blood clot. The risk is highest for smoking-related forms of cancer, such as lung and pancreatic cancer.
Scientists developed a high-speed microscopy platform that can measure tumor sensitivity to drugs in hours, rather than days, and has shown promising results in treating melanoma
Researchers from SU2C and Cancer Research Institute found that administering immunotherapy before surgery activates T-cells to hunt and destroy distant cancerous cells, preventing relapse. The approach showed encouraging outcomes in 45% of patients, with few evidence of cancer remaining upon follow-up.
A preclinical study by MD Anderson Cancer Center researchers found that precancerous colon polyps in patients with Lynch syndrome display immune system activation, challenging traditional models of cancer immune activation. The study suggests immunotherapy may be useful for colorectal cancer prevention in certain high-risk groups.
The SU2C Multiple Myeloma Dream Team aims to revolutionize the treatment of the incurable blood cancer by detecting precursor conditions such as MGUS or SMM. The team plans to analyze blood samples from approximately 50,000 people to identify biomarkers that can predict high-risk progression.
Researchers found that giving patients a single dose of anti-PD-1 therapy before surgery can predict tumor response and patient outcomes. The study also revealed that immune cells active against cancer were present in patients with longer recurrence-free survival.
A phase I clinical trial of BLU-667, a novel precision-targeted drug, reports significant durable disease control in patients with RET-driven cancers. The study reveals an overall response rate of 37% for RET-driven cancers, with responses of 45% for non-small cell lung cancer.
A study found that patients with a treating pivot nurse had higher patient satisfaction scores and better quality-of-life outcomes compared to those without such support. The coordinated care improved patients' understanding of their disease, treatment side-effects, and overall strength in fighting cancer.
A new study reports that consuming high amounts of carbohydrates and sugar prior to treatment for head and neck cancer may increase patients' risks of cancer recurrence and mortality. However, moderate fat and starchy food consumption after treatment appears to have protective benefits, reducing disease recurrence and death rates.
A lifestyle consistent with American Cancer Society (ACS) guidelines was associated with a lower risk of death in patients with stage III colon cancer. Patients who followed these guidelines had improved survival rates compared to those who did not.
Researchers found that simultaneous chemotherapy and immunotherapy is safe and patients with certain genetic mutations may respond particularly well. The combination approach was shown to boost immune cells in the blood, allaying previous concerns about chemotherapy's impact on immunotherapy.
A new NCI study revises molecular classification for diffuse large B-cell lymphoma, identifying four prominent genetic subtypes that can help explain treatment response. The study's findings will aid in predicting prognosis and tailoring therapy for patients with DLBCL.
Research analysis found unintended weight loss to be the second-highest risk factor for some forms of cancer. The study of 11.5 million patients revealed significant associations with colorectal, lung, pancreatic, and renal cancers, emphasizing the need for streamlined services to investigate non-specific symptoms like weight loss.
A study found that only 16% of respondents were aware of drug shortages, and those with a personal history of cancer were more likely to be aware. Most respondents wanted to be informed about substitution due to shortages and would transfer care to avoid major differences in efficacy.
A large study of breast cancer patients found that radiotherapy and chemotherapy do not significantly increase the risk of heart disease. Good risk management in hospitals and short interval screenings may offset elevated risks. The study's findings are considered positive for treatment of breast cancer.
A groundbreaking cancer genomics study reveals new molecular classifications, enabling the re-classification of 33 tumor types into 28 distinct clusters. These findings hold promise for immune-based and other novel cancer therapeutics, as well as repurposing drugs used to treat other diseases.
The PDX Finder is a free global portal for cancer models, offering over 1900 clinically relevant models from multiple repositories. Researchers can search and submit their own models to accelerate collaborative research and time-saving.
Researchers analyzed genomic and molecular data from 33 cancer types and identified 28 molecular clusters. The study provides new insights into cancer classification and potential treatment options.
Researchers have developed a new classification system for cancer based on molecular characteristics, identifying 28 subtypes and improving treatment options. The new approach has the potential to revolutionize cancer diagnosis and patient care.
Researchers created patient-specific bladder cancer organoids that mimic actual tumors, allowing for testing of multiple drugs and predicting individual response to treatment. The use of these personalized models may improve understanding of the genomics of bladder cancer and develop new therapies.
Scientists at the Medical University of South Carolina discovered a specific form of transforming growth factor-beta (TGF-beta) that binds to glycoprotein-A repetitions predominant (GARP), regulating B cell activity. The GARP:TGF-beta axis may serve as a diagnostic marker and therapeutic target for autoimmune diseases.
The NIH has completed a comprehensive genomic analysis of 33 cancer types, revealing new insights into tumor origins, progression, and vulnerabilities. The PanCancer Atlas provides a detailed understanding of how tumors arise in humans, enabling better informed clinical trials and future treatments.
A new approach to treating malignant pleural effusion in cancer patients combines talc with an indwelling pleural catheter, allowing for effective home-based treatment. The study found that patients treated with this combination were more than twice as likely to have their fluid dry up compared to those treated with IPC alone.
The American Cancer Society has approved funding for 110 grants totaling $47,624,000 to researchers at 72 institutions. Grants focus on improving treatments for various types of cancer, including lymphoma, breast cancer, and sarcomas.
Researchers have discovered a new function of the APC protein, which puts the brakes on colon cancer activators. This finding may lead to identification of additional drug targets and improved therapeutic strategies for colon cancer patients.
Researchers found that gut microbiome manipulation can significantly boost efficacy of adoptive T cell therapy in mice with cancer. Fecal transplants and antibiotic use increased anti-tumor response and remission rates, highlighting a crucial role for the gut microbiota in cancer treatment.
Researchers found a single upfront genomic test to be more effective for detecting Lynch syndrome in colorectal cancer (CRC) patients than traditional multiple testing. This approach helps guide treatment decisions while identifying those at risk of developing CRC and other cancers.
Larotrectinib, a new pediatric cancer drug targeting the TRK gene fusion, showed an unprecedented 93 percent response rate in patients tested. The drug has been effective in treating rare pediatric cancers such as infantile fibrosarcoma and papillary thyroid cancer.
Patients with alcohol-related liver cancer tend to have poorer overall survival rates compared to those with non-alcohol related liver cancer. The study highlights the need for improved screening and treatment programs for patients at risk of developing cirrhosis or liver cancer, especially those who are still drinking.
A global clinical trial collaboration published in the New England Journal of Medicine found that stage III colon cancer patients can cut their chemotherapy treatments in half after surgery, reducing costs and side effects. For low-risk patients with shallow tumors and few affected lymph nodes, a three-month course is shown to be safe ...
The SU2C Phillip A. Sharp Innovation in Collaboration Awards aim to strengthen collaboration among scientists conducting cancer research, with five teams receiving $1.25 million to work on new projects across institutional and national lines. The grants focus on synergies among researchers from different institutions and skill sets.
The BIABooster device characterizes DNA in blood circulation with new precision and sensitivity, identifying promising signatures for cancer monitoring. It has been shown to detect DNA up to a concentration of 10 fg/μL with precisions of 20% and 3%.
A pen and paper chart, EPAT, helps doctors regularly record pain levels using a traffic light system, leading to reduced pain in cancer patients, and improved monitoring of medications and side effects. The study suggests this simple approach can put pain management at the forefront of routine care, with potential benefits for patients.
A Singapore-led team of Asian cancer researchers has won the prestigious AACR Team Science Award for their groundbreaking work on cancers prevalent in Asia. The team's research has identified new genes and pathways, translated findings into clinical trials, and informed government policies.
Researchers analyzed 5,298 patients with surgically removed ampullary tumors and found no survival benefit from adjuvant therapy. Patients receiving additional chemotherapy or radiation therapy did not show improved stage-specific survival rates compared to those who underwent surgery alone.
A recent NRG Oncology study found that high-dose radiotherapy improves biochemical control and reduces distant metastases in men with intermediate-risk prostate cancer, but does not enhance overall survival. The treatment also resulted in more side effects compared to standard radiotherapy.
A newly designed chimera could simultaneously decrease the expression of three growth factors that are over-expressed in some cancers, leading to cancer cell death. The molecule has potent anti-tumor activity and is non-toxic, simple to produce, and cost-effective compared to traditional treatment strategies.
Researchers at Johns Hopkins Medicine have developed a non-invasive test called UroSEEK, which uses urine samples to detect DNA mutations associated with bladder cancer. The test significantly enhances early detection for patients at risk and surveillance of those who have already been treated. When combined with cytology, the sensitiv...
A new model predicts the extra risk of death for breast cancer patients and survivors, taking into account improved survival rates over time. The model could lead to lower life insurance premiums and increased transparency for patients.
A study found that patients with ductal carcinoma in situ (DCIS) who are post-menopausal or estrogen receptor positive have a low risk of recurrence. Treatment with breast-conserving surgery and radiotherapy leads to very low rates of recurrence. The research also identifies clues for tailoring treatments to individual patients.